Authors
Latest:
Nadofaragene firadenovec maintains safety, efficacy in real-world population"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH.
Latest:
Matthew Mutter, MD, shares data on Separo vessel sealing system for vasectomy"I want to add that the safety profile was impeccable for this. No one experienced a [device-related] adverse event," says Matthew J. Mutter, MD.
Latest:
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomyShay Rajavel, MS3, shares details on an AUA 2025 presentation on CO2 gas embolism during laparoscopic surgery.
Latest:
As Patients Live Longer, New Criteria Needed for Prostate Cancer TrialsResearchers sought to understand if a lack of cancer progression as monitored by radiography could substitute overall survival as a metric for metastatic prostate cancer clinical trials.
Latest:
Encouraging antitumor activity seen with neoadjuvant enfortumab vedotin in patients with cisplatin-ineligible MIBC“This first disclosure of data supports the ongoing phase 2 and 3 programs evaluating enfor-tumab vedotin alone or in combination with pembrolizumab in MIBC,” said Daniel P. Petrylak, MD.
Latest:
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options“It is likely that more and more, these newer agents are going to play earlier and more central roles in the early treatment of BCG-unresponsive disease," says Shreyas S. Joshi, MD, MPH.
Latest:
Gautam Jayram, MD, on key bladder cancer agents to keep an eye on"There's a ton of activity in this space, and I think every 6 to 12 months, we're going to keep getting these boluses of information that's going to help us," says Gautam Jayram, MD.
Latest:
Update offers clues to optimal olaparib use in prostate cancerThe latest findings for the PARP inhibitor in prostate cancer come from an analysis of the pivotal phase 3 PROfound trial presented during the 2021 AUA Annual Meeting.
Latest:
Bladder preservation in localized, muscle-invasive bladder cancer: Current state of affairs“In the highly selected patient with localized MIBC, an organ-preserving approach to treatment may produce similar oncologic outcomes to radical surgery with a potential for improved QoL, although there is currently insufficient evidence to recommend bladder preservation therapy as a standard of care," the authors write.
Latest:
Coaching program aims to alleviate female physician burnoutCofounders Adrienne Mann, MD, and Tyra Fainstad, MD, discuss Better Together, a professional, structured coaching program designed to address the burnout experienced by women in medicine.
Latest:
Call for Abstract, Workshop, and Roundtable Submissions for PFD Week 2025Submit your abstract and/or roundtable and workshop proposal for PFD Week 2025, to be held October 14-17 in Vancouver, Canada!
Latest:
Bladder preservation in localized, muscle-invasive bladder cancer: Current state of affairs“In the highly selected patient with localized MIBC, an organ-preserving approach to treatment may produce similar oncologic outcomes to radical surgery with a potential for improved QoL, although there is currently insufficient evidence to recommend bladder preservation therapy as a standard of care," the authors write.
Latest:
Urology PA on how the Surgical Impotence Management Strategy program results in better informed patients"I think that as patients go through this, it's a reminder that it's very scary," says MIchael Jenson, PA-C.
Latest:
Darolutamide linked to fewer hospitalizations in patients with mHSPCCompared with placebo, darolutamide was associated with a numerically lower rate of hospitalizations when combined with androgen-deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer.
Latest:
Fertility preservation in patients with testicular cancer"Full discussion of the various fertility preservation options and an understanding of the fertility implications of the various treatment modalities must be understood by patients for them to make optimal decisions for their reproductive futures," write the authors.
Latest:
Diversity in Urology: Progress made, but there is more work to be doneKelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.
Latest:
Future Directions for Imaging and Biopsy in Prostate CancerThe panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.
Latest:
Everything you need to know about medical coding and billing auditsThrough medical claims audits, the practice can help protected itself against fraudulent billing activity and claims.
Latest:
Overview of Advanced/Metastatic Prostate CancerIn the first article of this series, Nilay Gandhi, MD, explains the treatment and management of patients with advanced/metastatic prostate cancer and details the options for androgen deprivation therapy.
Latest:
Tips for physicians to improve work-life balanceOverworking has become the norm, but that doesn’t mean it should be.
Latest:
Case report details spontaneous bladder rupture caused by herpes zoster–associated urinary retentionAlthough cases of acute urinary retention and defecation caused by herpes zoster in the sacral area have been reported, no clinical cases about spontaneous bladder rupture have been previously published, according to the authors.
Latest:
Molecular diagnostic practice in prostate and bladder cancers"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.
Latest:
Strategies to mitigate impact of intravenous ICM shortage"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.
Latest:
Future Perspectives in the Treatment of Patients With Urinary StonesDrs Bechis and Semins discuss future developments in urinary stone management, emphasizing the potential for improved vacuum aspiration devices, combined intravenous and PCNL surgeries, and the hope for medications to dissolve stones.
Latest:
Money Matters: Informing your perspective on the bear marketNo matter what your age or risk tolerance, investing is a lot easier and likely more successful if your perspective is informed by market history.
Latest:
Expert explains challenges of telehealthAlthough much of the discourse around telehealth rightfully focuses on its benefits, the potential drawbacks and limitations are often glossed over, particularly around provider burden.
Latest:
Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder CancerPanelists discuss how they approach a typical bladder cancer case of a 79-year-old man with hematuria, including initial diagnostic procedures, the importance of proper tumor measurement during resection, BCG therapy protocols, and management options for BCG-unresponsive disease with a focus on nadofaragene firadenovec (Adstiladrin).
Latest:
Ensuring operational continuity is critical with healthcare data breachesWith healthcare data breaches approaching a boiling point, care providers need to adopt an approach that prioritizes operational continuity.
Latest:
Anktiva as a lymphocyte rescue molecule: Unlocking the power of NK cells and T cells"One way to think about how Anktiva works is it is the first molecule, based on the package insert, that increases and proliferates the NK cells, the T cells, and the CD4+ and CD8+ T cells, without up-regulating the suppressive T cells," says Patrick Soon-Shiong, MD.
